Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 10-K stay in one workspace.
ADAPY
$0.03
+11.30%
ADAPY
· Adaptimmune Therapeutics PLC
$0.03
+0.00 (+11.30%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2025
Substantial doubt about the company's ability to continue as a going concern.
“the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued.”View the 10-Q filed Aug 13, 2025
Market Cap
$43.73M
Shares
1.59B
Volume · Oct 20
91.02K
Avg daily vol (3M)
144.7K
All webcasts
Earnings call · FY2023 Q4
Adaptimmune Therapeutics PLC (ADAPY) Q4 2023 Earnings Call
Revenue · derived Q4
$231,000
-97.9% YoY
Net income · derived Q4
-$47.92M
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Research materials
Open the source you need; every reader stays inside this workspace.
SEC filing · Item 2.02
8-K earnings release
Filed Mar 6, 2024 · complete as-filed document
SEC periodic report
10-K report
Filed Mar 6, 2024 · complete as-filed document